Stoke Therapeutics said Monday that a higher dose of its experimental drug for epilepsy reduced the frequency of convulsive seizures in children with a rare form of the disease. However, the treatment effect was still too low to provide a meaningful benefit, raising concerns that the company’s approach may never work.
In the update to a mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-milligram dose, resulted in a median 55% reduction in convulsive seizure activity, compared to baseline.